Reversing Multidrug Resistance via Efficient Inhibition of Drug Efflux for Enhanced Cancer Therapy
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202505701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Xinhe Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Drug Resistance, Multiple, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Henan Province, Key Scientific Research Project of Colleges and Universities in Henan Province.
Abstract (Originalsprache)
Multidrug resistance (MDR) mediated by P‐glycoprotein (P‐gp) remains a primary obstacle for successful cancer chemotherapy. Effective inhibition of P‐gp transport is important for high efficacy of chemotherapeutic drugs. Herein, a smart platform (CaO 2 @HA‐CAT‐DOX‐FA) is proposed to reduce the expression of P‐gp through the combination of hypoxia alleviation and adenosine triphosphate (ATP) suppression, thereby effective diminishing the efflux of chemotherapeutic drug. Hyaluronic acid (HA) can protect calcium peroxide (CaO 2 ) from premature depletion. The nanocomposite is further conjugated with folic acid (FA) to endow it with tumor‐targeting ability. At the tumor site, the nanocomposite disintegrates and releases calcium ion (Ca 2+ ), doxorubicin (DOX), catalase (CAT), and coincidentally produces a large amount of hydrogen peroxide (H 2 O 2 ) in the acidic tumor microenvironment (TME) containing hyaluronidase. Subsequently, CAT can catalyze the transformation of H 2 O 2 into oxygen (O 2 ) ameliorating the hypoxia. Ca 2+ ‐overloading‐induced mitochondrial dysfunction can interrupt ATP synthesis and restrain cellular respiration decreasing O 2 consumption. With the combination of relieving hypoxia and suppressing ATP production, the expression of P‐gp was remarkable downregulated, thereby overcoming MDR, with confirmed by in vitro and in vivo experiments. This study may provide new avenues for the treatment of multidrug‐resistant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.
- Henan International Joint Laboratory of Smart Molecules and Identification and Diagnostic Functions, Henan Normal University, Xinxiang, China.
- Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
- Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Normal University, Xinxiang, China.
ORCID-Profile: Yuming Guo
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Henan Province
- Key Scientific Research Project of Colleges and Universities in Henan Province
- Higher Education Discipline Innovation Project
Zitieren
APA
Liu, X., Tian, Y., Zang, D., Chang, Y., Zhai, J., Kong, C., Zhang, J., Gao, F., Yang, P., Ma, X., Yang, L., & Guo, Y. (2026). Reversing Multidrug Resistance via Efficient Inhibition of Drug Efflux for Enhanced Cancer Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202505701
Vancouver
Liu X, Tian Y, Zang D, Chang Y, Zhai J, Kong C, et al. Reversing Multidrug Resistance via Efficient Inhibition of Drug Efflux for Enhanced Cancer Therapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202505701
BibTeX
@article{Liu2026,
author = {Liu, Xinhe and Tian, Yunchuan and Zang, Dan and Chang, Yi and Zhai, Jiaying and Kong, Cuicui and Zhang, Jie and Gao, Fangli and Yang, Pengfei and Ma, Xiaoming and Yang, Lin and Guo, Yuming},
title = {Reversing Multidrug Resistance via Efficient Inhibition of Drug Efflux for Enhanced Cancer Therapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202505701}
}
EUVIMED